Scientific Update – Radiation-releasing “seeds” may slow cholangiocarcinoma growth by inhibiting VEGFR2 singling

External radiation has been used to treat cancer for many years, but recent technological advances have led to a new form of radiation from implanted iodine 125 (125I) “seeds.” This new approach is advantageous since it allows high doses of targeted radiation with minimal damage to surrounding tissues while being more convenient for patients than…

Read More

Scientific Update – Circular RNA (circZNF215) in cholangiocarcinoma: A new possible therapeutic target

About 98% of the human genome is non-coding, meaning it does not contain the genetic code to make proteins. However, these non-coding regions are not “junk DNA.” Instead, they contain important regulatory elements that can affect gene expression, protein levels, and protein activity. One type of non-coding element is circular RNAs, and a recent study…

Read More

Monthly Scientific Update – May 2023

APOBEC3-Mediated Mutagenesis in Cholangiocarcinoma Many enzymes are involved in the immune response to viruses and APOBEC3s are a class of those enzymes. APOBEC3s are expressed in cells as soon as a virus enters the body and they help eliminate it by damaging its genome. However, APOBEC3s can also act on host cell DNA, leaving it…

Read More

Monthly Scientific Update – April 2023

Radiomics Models May Help Identify Candidates for Surgery Most cholangiocarcinoma tumors are unfortunately detected at advanced stages, but surgical resection is sometimes possible for earlier-stage cancers. To better identify patients who may benefit from surgery, researchers are working to develop ways to predict postoperative disease recurrence. A recent study thus identified variables associated with post-surgical…

Read More

Monthly Scientific Update – March 2023

Asbestos and Cholangiocarcinoma: A Pilot Study Kelly Butler Asbestos is a mineral-derived carcinogen linked to multiple human cancers. Although asbestos has been removed from thousands of commonly used consumer products, occupational and environmental exposures are still important cancer risk factors. A recent study thus sought to understand better whether asbestos is linked to cholangiocarcinoma. Forty…

Read More

Monthly Scientific Update – February 2023

LCK Inhibitor: A Novel Potential Therapy for Cholangiocarcinoma A variety of signaling pathways can become overactive in cancer to promote cell growth. One of these pathways is known as the Hippo signaling pathway, which involves the activation of “yes-associated protein” (YAP). YAP is regulated by another protein called LCK, which can turn on YAP through…

Read More

Monthly Scientific Update – November 2022 (A recent study investigated the effects of PD-L1 expression on cancer cells and tumor-infiltrating immune cells in intrahepatic cholangiocarcinoma (CCA))

PD-L1 on Tumor-Infiltrating Immune Cells: A Potential Prognostic Biomarker for Cholangiocarcinoma Kelly Butler, Dr. Reham Abdel-Wahab Patients may develop cancer when some organ cells acquire mutations that allow rapid and uncontrolled cell proliferation. To survive and spread beyond the initial tumor site, cancer cells must stop the body’s immune system from identifying the cells as…

Read More

Monthly Scientific Update – October 2022 (Breath Tests Could Help Diagnose Cholangiocarcinoma: An Innovative Approach to Early Detection)

Kelly Butler, Dr. Reham Abdel-Wahab Cholangiocarcinoma (CCA) is often detected at an advanced stage that is difficult to treat. Early detection is an important area of research, and scientists are working to develop new tools to detect CCA in its early, more treatable stages. A recent paper laid the necessary groundwork for diagnostic breath tests,…

Read More

Monthly Scientific Update – September 2022 (Precision Therapeutics for Intrahepatic Cholangiocarcinoma)

Kelly Butler, Dr. Reham Abdel-Wahab The traditional chemotherapies gemcitabine and cisplatin have several side effects and have been used to treat cholangiocarcinoma for decades. However, the field of precision oncology is rapidly advancing and generating new, more targeted treatment options. Every tumor is unique, and precision oncology examines the specific genetic alterations in a patient’s…

Read More

Monthly Scientific Update – August 2022 (Preclinical Study Finds that Brusatol may Slow Intrahepatic Cholangiocarcinoma Growth)

Kelly Butler, Dr. Reham Abdel-Wahab Brusatol, a traditionally used Chinese herbal medicine, is currently being explored as a potential cancer treatment in preclinical studies. While the research is still in its early stages,  several studies have found promising results in models of multiple cancer types. A recent laboratory study focused specifically on intrahepatic cholangiocarcinoma (ICC)…

Read More

Monthly Scientific Update – July 2022 (Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures)

Kelly Butler, Dr. Reham Abdel-Wahab A recent study in Precision Oncology examined the diverse genetic and molecular profiles of biliary tract cancers (BTCs). With an eye toward therapeutic value, the study aimed to identify characteristics of each BTC subtype that confer responsiveness to targeted therapies and immunotherapies.  The researchers examined a group of 454 BTC…

Read More

Monthly Scientific Update – June 2022 (Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs. Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma)

The role of locoregional therapy in treating intrahepatic cholangiocarcinoma (iCCA) patients is still limited. Therefore, a group of researchers assessed if using a hepatic arterial infusion pump (HAIP) to deliver high-dose chemotherapy directly into the liver is similar to surgical resection. The researchers enrolled 319 patients with multifocal iCCA, including 141 patients in the HAIP…

Read More

Monthly Scientific Update – May 2022 (Ramucirumab)

Recently, a group of researchers designed a phase II, single-arm clinical trial to evaluate the use of Ramucirumab in the treatment of advanced biliary tract cancer patients. Ramucirumab is a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR-2). The researchers enrolled patients with ECOG performance status 0-1 who were previously treated with gemcitabine-based…

Read More

Monthly Scientific Update – April 2022 (the impact of Capecitabine (Xeloda) as adjuvant therapy for surgically resected biliary tract cancers)

Recently, a group of medical oncologists assessed the long-term outcome of a randomized phase III BILCAP trial to evaluate the impact of Capecitabine (Xeloda) as adjuvant therapy for surgically resected biliary tract cancers. Between 2006 and 2014, 447 patients with resectable biliary tract cancer were enrolled in this study. After resecting the tumor, patients were randomized into two…

Read More

Monthly Scientific Update – March 2022

Carl Scheitrum spent more than 1,000 volunteer hours in 2021 updating the International Cholangiocarcinoma Patient Registry. Carl’s information technology experience played a crucial role in this project. He helped the CCF team explore the best approaches to make this registry platform more patient-friendly. He also focused on improving the registry output, so researchers can use…

Read More